Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Jeste, D. V. Articles by Martinez, R. A. Search for Related Content PubMed Citation Articles by Jeste, D. V. Articles by Martinez, R. A. Geriatric Psychiatry Dementias (General) Other Neuroleptics

Low Incidence of Persistent Tardive Dyskinesia in Elderly Patients With Dementia Treated With Risperidone

OBJECTIVE: The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone.METHOD: After participating in a 12-week multicenter double-blind study during which they received placebo or one of three doses of risperidone, 330 patients (mean age=82.5 years) with Alzheimer’s, vascular, or mixed dementia were enrolled in a 1-year open-label study during which they received flexible doses of risperidone. Persistent emergent tardive dyskinesia was defined according to scores on the dyskinesia subscale of the Extrapyramidal Symptom Rating Scale.RESULTS: The mean modal risperidone dose was 0.96 mg/day (SD=0.53), and the median length of risperidone use was 273 days. The 1-year cumulative incidence of persistent emergent tardive dyskinesia among the 255 patients without dyskinesia at baseline was 2.6%. Patients with dyskinetic symptoms at baseline experienced significant reductions in the severity of dyskinesia. Patients who received 0.75–1.5 mg/day of risperidone showed a significant improvement in psychopathologic symptoms over the 1-year period.CONCLUSIONS: Although there was no control group, the observed incidence of persistent tardive dyskinesia with risperidone seemed to be much lower than that seen in elderly patients treated with conventional neuroleptics. The average optimal dose of risperidone in elderly dementia patients was found to be 0.75–1.5 mg/day.

This article has been cited by other articles:

				D. D. Miller, S. N. Caroff, S. M. Davis, R. A. Rosenheck, J. P. McEvoy, B. L. Saltz, S. Riggio, M. H. Chakos, M. S. Swartz, R. S. E. Keefe, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial The British Journal of Psychiatry, October 1, 2008; 193(4): 279 - 288. [Abstract] [Full Text] [PDF]

				R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak Rethinking Antipsychotic Formulary Policy Schizophr Bull, March 1, 2008; 34(2): 375 - 380. [Abstract] [Full Text] [PDF]

				J. M. Noel ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 863 - 876. [Full Text] [PDF]

				D. V. Jeste, T. W. Meeks, D. S. Kim, and G. S. Zubenko Research Agenda for DSM-V: Diagnostic Categories and Criteria for Neuropsychiatric Syndromes in Dementia J Geriatr Psychiatry Neurol, September 1, 2006; 19(3): 160 - 171. [Abstract] [PDF]

				G. REMINGTON Rational pharmacotherapy in early psychosis The British Journal of Psychiatry, August 1, 2005; 187(48): s77 - s84. [Abstract] [Full Text] [PDF]

				D. E. ROSS Tardive Dyskinesia and Second-Generation Antipsychotics Am J Psychiatry, February 1, 2005; 162(2): 405 - 405. [Full Text] [PDF]

				M. J Ehret and M. A Fuller Long-Acting Injectable Risperidone Ann. Pharmacother., December 1, 2004; 38(12): 2122 - 2127. [Abstract] [Full Text] [PDF]

				S. J. Bartels, A. R. Dums, T. E. Oxman, L. S. Schneider, P. A. Arean, G. S. Alexopoulos, and D. V. Jeste Evidence-Based Practices in Geriatric Mental Health Care Focus, April 1, 2004; 2(2): 268 - 281. [Abstract] [Full Text] [PDF]

				C. U. Correll, S. Leucht, and J. M. Kane Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Am J Psychiatry, March 1, 2004; 161(3): 414 - 425. [Abstract] [Full Text] [PDF]

				G. T. Grossberg and A. K. Desai Management of Alzheimer's Disease J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M331 - 353. [Full Text] [PDF]

				O. L. Lopez, J. T. Becker, R. A. Sweet, W. Klunk, D. I. Kaufer, J. Saxton, and S. T. DeKosky Patterns of Change in the Treatment of Psychiatric Symptoms in Patients With Probable Alzheimer's Disease From 1983 to 2000 J Neuropsychiatry Clin Neurosci, February 1, 2003; 15(1): 67 - 73. [Abstract] [Full Text] [PDF]

				S. J. Bartels, A. R. Dums, T. E. Oxman, L. S. Schneider, P. A. Arean, G. S. Alexopoulos, and D. V. Jeste Evidence-Based Practices in Geriatric Mental Health Care Psychiatr Serv, November 1, 2002; 53(11): 1419 - 1431. [Abstract] [Full Text] [PDF]

				R. A. Maxwell, R. A. Sweet, B. H. Mulsant, J. Rosen, M. A. Kirshner, K. B. Kastango, and B. G. Pollock Risperidone and 9-Hydroxyrisperidone Concentrations Are Not Dependent on Age or Creatinine Clearance among Elderly Subjects J Geriatr Psychiatry Neurol, June 1, 2002; 15(2): 77 - 81. [Abstract] [PDF]

				R. K. Schneider and J. L. Levenson Update in Psychiatry Ann Intern Med, February 19, 2002; 136(4): 293 - 301. [Full Text] [PDF]

				W. P. Bouman and G. Pinner Use of atypical antipsychotic drugs in old age psychiatry Advan. Psychiatr. Treat., January 1, 2002; 8(1): 49 - 58. [Full Text] [PDF]

				S. N. GHAEMI and J. Y. KO Quetiapine-Related Tardive Dyskinesia Am J Psychiatry, October 1, 2001; 158(10): 1737 - 1737. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us